Roles of 2-Deoxyglucose in the Treatment of Papillary Thyroid Carcinoma and Neuroblastoma
博士 === 長庚大學 === 臨床醫學研究所 === 103 === The purpose of this research was to investigate the changes in mitochondrial DNA (mtDNA) associated with the BRAFV600E mutation in papillary thyroid carcinoma (PTC), and the role of 2-deoxyglucose (2-DG), a glycolysis inhibitor, in PTC and neuroblastoma (NB). PTC...
Main Authors: | Shuo Yu Wang, 王碩郁 |
---|---|
Other Authors: | J. H. Chuang |
Format: | Others |
Published: |
2015
|
Online Access: | http://ndltd.ncl.edu.tw/handle/81117773642412890544 |
Similar Items
-
Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth in mice
by: Chao-Cheng Huang, et al.
Published: (2015-10-01) -
Sorafenib and 2-Deoxyglucose: The Future of Hepatocellular Carcinoma Therapy
by: Reyes, Ryan
Published: (2016) -
Coexistence of Hashimoto's thyroiditis and papillary thyroidal carcinoma with papillary carcinoma of thyreoglossal duct
by: Čizmić Milica, et al.
Published: (2007-01-01) -
Anaplastic thyroid carcinoma diagnosed after treatment of lenvatinib for papillary thyroid carcinoma
by: Haruhiko Yamazaki, et al.
Published: (2019-10-01) -
The Role of Fragile Sites in Sporadic Papillary Thyroid Carcinoma
by: Laura W. Dillon, et al.
Published: (2012-01-01)